The DOI matches its Crossref record.
FTY720, A Novel Immunomodulator: Efficacy and Safety Results from the First Phase 2A Study in de novo Renal Transplantation
Abstract
BACKGROUND: FTY720 is the first of a new drug class: sphingosine-1-phosphate receptor agonist. Its effect relates to the modulation of lymphocytes trafficking from blood and peripheral tissues to lymph nodes. This is the first study to evaluate the efficacy and safety of FTY720 in de novo renal transplantation. METHODS: This phase 2a, multicenter, open-label, dose-finding study compared FTY720 (0.25, 0.5, 1.0, or 2.5 mg) with mycophenolate mofetil (MMF), in combination with cyclosporine and corticosteroids. Patients (n=208) received FTY720 (n=167) or MMF (n=41) for 3 months followed by a 3-month follow-up. RESULTS: The incidence of biopsy-confirmed acute rejection at month 3 was 23.3%, 34.9%, 17.5%, and 9.8%, respectively, with FTY720 at doses of 0.25, 0.5, 1.0, and 2.5 mg, versus 17.1% with MMF. The incidence for the composite endpoint (biopsy-confirmed acute rejection, graft loss, or death) was lowest with FTY720 at a dose of 2.5 mg at month 3 (14.6%) compared with FTY720 at doses of 0.25 mg (25.6%), 0.5 mg (34.9%), and 1.0 mg (17.5%), and MMF (19.5%). Safety was comparable between FTY720 and MMF group. The main difference in tolerability was a mild and transient reduction in heart rate. A decrease in peripheral lymphocytes occurred in patients receiving FTY720, as expected from the mode of action, and this was reversible after treatment cessation. CONCLUSIONS: FTY720 at 2.5 mg was found to be as effective as MMF in combination with cyclosporine for the prevention of acute rejection after renal transplantation. FTY720 was well tolerated and not associated with the side effects commonly observed with immunosuppressant therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis
Brinkmann, V., Billich, A., Baumruker, T., Heining, P., Schmouder, R., Francis, G., Aradhye, S., & Burtin, P. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3248 · Cited by 1,273
Oral Fingolimod (FTY720) for Relapsing Multiple Sclerosis
Kappos, L., Antel, J., Comi, G., Montalban, X., O'Connor, P., Polman, C. H., Haas, T., Korn, A. A., Karlsson, G., & Radue, E. W. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa052643 · Cited by 1,054
“Inside-Out” Signaling of Sphingosine-1-Phosphate: Therapeutic Targets
Takabe, K., Paugh, S. W., Milstien, S., & Spiegel, S. (2008) · Pharmacological Reviews · doi:10.1124/pr.107.07113 · Cited by 718
Choi, J. W., Gardell, S. E., Herr, D. R., Rivera, R., Lee, C.-W., Noguchi, K., Teo, S. T., Yung, Y. C., Lu, M., Kennedy, G., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1014154108 · Cited by 581
Brinkmann, V. (2007) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2007.04.006 · Cited by 528
Metadata
- Authors
- Tedesco-Silva, H., Mourad, G., Kahan, B. D., Boira, J. G., Weimar, W., Mulgaonkar, S., Nashan, B., Madsen, S., Charpentier, B., Pellet, P., & Vanrenterghem, Y.
- Venue
- Transplantation
- Published
- 2005-06-15
- Volume
- 79
- Issue
- 11
- Pages
- 1553-1560
- ISSN
- 0041-1337 (ISSN-L)
- OpenAlex
- W1981802180
- Cited by
- 215
- References
- 0
- FWCI
- 21.52
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: FTY720, A Novel Immunomodulator: Efficacy and Safety Results from the First Phase 2A Study in de novo Renal Transplantation. https://app.cochat.ai/papers/10.1097/01.tp.0000121761.02129.a6
- The paper
- Tedesco-Silva, H., Mourad, G., Kahan, B. D., Boira, J. G., Weimar, W., Mulgaonkar, S., Nashan, B., Madsen, S., Charpentier, B., Pellet, P., & Vanrenterghem, Y. (2005). FTY720, A Novel Immunomodulator: Efficacy and Safety Results from the First Phase 2A Study in de novo Renal Transplantation. Transplantation. https://doi.org/10.1097/01.tp.0000121761.02129.a6
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.